The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice

Infection and Immunity

Volumn 79, Issue 10, 2011, Pages 4010-4018

  Norris, Michael H ^a   Propst, Katie L ^b   Kang, Yun ^a   Dow, Steven W ^b   Schweizer, Herbert P ^b   Hoang, Tung T ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMINOPIMELIC ACID; LIVE VACCINE;

ACUTE INHALATION MELIOIDOSIS; ANIMAL CELL; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM MUTANT; BAGG ALBINO MOUSE; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; CYTOPATHOLOGY; CYTOTOXICITY; GIANT CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INHALATION; MACROPHAGE; MELIOIDOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ACUTE DISEASE; ANIMALS; ASPARTATE-SEMIALDEHYDE DEHYDROGENASE; BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; CELL LINE; DISEASE MODELS, ANIMAL; INHALATION; MACROPHAGES; MELIOIDOSIS; MICE; MICE, INBRED BALB C; SEQUENCE DELETION; VACCINES, ATTENUATED; VIRULENCE;

EID: 80855136620     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05044-11     Document Type: Article

References (45)

1. Atkins, T., et al. 2002. Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J. Med. Microbiol. 51:539-553.
2. Barrett, A. R., et al. 2008. Genetics tools for allelic-replacement in Burkholderia species. Appl. Environ. Microbiol. 74:4498-4508.
3. Belyakov, I. M., and J. D. Ahlers. 2009. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183:6883-6892.
4. Breitbach, K., J. Kohler, and I. Steinmetz. 2008. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans. R. Soc. Trop. Med. Hyg. 2008: S89-S94.
5. Buckley, A. M., et al. 2010. Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry. Vaccine 28:1094-1105.
6. Burtnick, M. N., et al. 2008. Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages. Infect. Immun. 76:2991-3000.
7. Cheng, A. C., and B. J. Currie. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416.
8. Choi, K.-H., et al. 2008. Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl. Environ. Microbiol. 74:1064-1075.
9. Cuccui, J., et al. 2007. Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important for survival and pathogenesis. Infect. Immun. 75:1186-1195.
10. Dance, D. A. B. 1991. Melioidosis: the tip of the iceberg? Clin. Microbiol. Rev. 4:52-60.
11. DeShazer, D., P. J. Brett, R. Carlyon, and D. E. Woods. 1997. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutant and molecular characterization of the flagellin structural gene. J. Bacteriol. 179:2116-2125.
12. Drabner, B., and C. A. Guzman. 2001. Elicitation of predictable immune responses by using live bacterial vectors. Biomol. Eng. 17:75-82.
13. Galan, J. E., K. Nakayama, and R. Curtiss. 1990. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 94:29-35.
14. Goodyear, A., et al. 2009. Protection from pneumonic infection with Burkholderia species by inhalational immunotherapy. Infect. Immun. 77:1579-1588.
15. + T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J. Infect. Dis. 194:1241-1248.
16. Haque, A., et al. 2006. Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J. Infect. Dis. 193:370-379.
17. Harb, O. S., and Y. A. Kwaik. 1998. Identification of the aspartate-betasemialdehyde dehydrogenase gene of Legionella pneumophila and characterization of a null mutant. Infect. Immun. 66:1898-1903.
18. Hatten, L.-A., H. P. Schweizer, N. Averill, L. Wang, and A. B. Schryvers. 1993. Cloning and characterization of the Neisseria meningitidis asd gene. Gene 129:123-128.
19. Haziza, C., P. Stragier, and J. C. Patte. 1982. Nucleotide sequence of the asd gene of Escherichia coli: absence of a typical attenuation signal. EMBO J. 1:379-384.
20. Hoang, T., S. Williams, H. P. Schweizer, and J. S. Lam. 1997. Molecular genetic analysis of the region containing the essential Pseudomonas aeruginosa asd gene encoding aspartate-β-semialdehyde dehydrogenase. Microbiology 143:899-907.
21. Jeddeloh, J. A., D. L. Fritz, D. M. Waag, J. M. Hartings, and G. P. Andrews. 2003. Biodefense-driven murine model of pneumonic melioidosis. Infect. Immun. 71:584-587.
22. Jones, A. L., T. J. Beveridge, and D. E. Woods. 1996. Intracellular survival of Burkholderia pseudomallei. J. Bacteriol. 64:782-790.
23. Kahl-McDonagh, M. M., and T. A. Ficht. 2006. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect. Immun. 74:4048-4057.
24. Kang, Y., M. H. Norris, A. R. Barrett, B. A. Wilcox, and T. T. Hoang. 2009. Engineering of tellurite-resistant genetic tools for single-copy chromosomal analysis of Burkholderia spp. and characterization of the Burkholderia thailandensis betBA operon. Appl. Environ. Microbiol. 75:4015-4027.
25. Kong, W., et al. 2008. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc. Natl. Acad. Sci. U. S. A. 105:9361-9366.
26. Lane, H. C., J. L. Montagne, and A. S. Fauci. 2001. Bioterrorism: a clear and present danger. Nat. Med. 7:1271-1273.
27. McCord, J. M., and K. Wong. 1979. Phagocyte-produced free radicals: roles in cytotoxicity and inflammation. John Wiley & Sons, Ltd., Hoboken, NJ.
28. Norris, M. H., Y. Kang, D. Lu, B. A. Wilcox, and T. T. Hoang. 2009. Glyphosate resistance as a novel select-agent-compliant, non-antibiotic-selectable marker in chromosomal mutagenesis of the essential genes asd and dapB of Burkholderia pseudomallei. Appl. Environ. Microbiol. 75:6062-6075.
29. Norris, M. H., Y. Kang, B. Wilcox, and T. T. Hoang. 2010. Stable, site-specific fluorescent tagging constructs optimized for Burkholderia species. Appl. Environ. Microbiol. 76:7635-7640.
30. Peacock, S. J., et al. 2008. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg. Infect. Dis. 14:e2.
31. Propst, K. L., T. Mima, K.-H. Choi, S. W. Dow, and H. P. Schweizer. 2010. A Burkholderia pseudomallei ΔpurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select- agent lists. Infect. Immun. 78:3136-3143.
32. Richmond, J. Y., and R. W. McKinney. 2007. Biosafety in microbiological and biomedical laboratories, 5th ed. Centers for Disease Control and Prevention, Atlanta, GA.
33. Roake, J. A., et al. 1995. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 181:2237-2247.
34. Rodrigues, F., et al. 2006. Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. J. Bacteriol. 188:8178-8188.
35. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
36. Schleifer, K. H., and O. Kandler. 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 36:407-477.
37. Spreng, S., and J.-F. Viret. 2005. Plasmid maintenance systems suitable for GMO-based bacterial vaccines. Vaccine 23:2060-2065.
38. Stavnezer, J. 1996. Immunoglobulin class switching. Curr. Opin. Immunol. 8:199-205.
39. Stevens, M. P., et al. 2003. A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide exchange factor activity. J. Bacteriol. 185:4992-4996.
40. Tacket, C. O., et al. 1997. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the asd-balanced lethal vector system. Infect. Immun. 65:3381-3385.
41. Titball, R. W., et al. 2008. Burkholderia pseudomallei: animal models of infection. Trans. R. Soc. Trop. Med. Hyg. 102:S111-S116.
42. Ulrich, R. L., K. Amemiya, D. M. Waag, C. J. Roy, and D. DeShazer. 2005. Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice. Vaccine 23:1986-1992.
43. U.S. Code of Federal Regulations. 2002. Public Health Security and Bioterrorism Preparedness and Response Act, 107th Congr. Public Law 107-18. 42 CFR 73.21.
44. Wiersinga, W. J., T. van der Poll, N. J. White, N. P. Day, and S. J. Peacock. 2006. Melioidosis: insight into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4:272-282.
45. Zhao, Z., et al. 2008. Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bordetella bronchiseptica. Infect. Immun. 76:2157-2163.